By Dean Seal
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy.
The stock was up 9.5% at 1.28 in premarket trading. Shares had fallen 25% year-to-date when the market closed last week.
The clinical-stage biopharma company said Monday that the Food and Drug Administration has lifted a clinical hold on ENTR-601-44 and authorized a Phase 1b clinical study of it as a potential treatment for Duchenne muscular dystrophy in certain adult patients.
"Given the strength of our safety and target engagement data from our Phase 1 clinical study and the profound unmet need in adults living with Duchenne, we are pleased to have obtained FDA clearance," Chief Executive Dipal Doshi said.
Entrada plans to launch enrollment for the study in the first half of 2026.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 24, 2025 07:32 ET (12:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。